S59. Response to immunotherapy in antibody-negative autoimmune epilepsy

Tiwana, Harmanpreet K.; Acharya, Vinita; Acharya, Jayant N.

doi:10.1016/j.clinph.2018.04.419

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there is currently no effective pediatric scale to identify the population in need of antibody testing, screening for AE is necessary to identify patients who may be eligible for immunotherapy and to avoid overuse of ASM and excessive psychological stress for parents. Since not all antibodies have been discovered and reported, and not all discovered antibodies can be detected, negative MRI results of antibodies, cerebrospinal fluid, and brain do not exclude the possibility of AE ( 31 , 32 ). For newly emerged seizures of short duration and high frequency with poor response to ASMs, and the exclusion of other clear causes in pediatric patients, the possibility of AE should be considered, with the relevant antibody screening carried out as soon as possible.…”

Section: Discussionmentioning

confidence: 99%

The value of immunotherapy in children with initial short-term frequent seizures

Zhao

Gao

et al. 2022

Front. Neurol.

View full text Add to dashboard Cite

This study aimed to discuss clinical characteristics, therapy, and antibody prevalence in epilepsy (APE) score for short-term, frequent epileptic seizures in children who are autoimmune-antibody negative and respond well to immunotherapy. The clinical characteristics, imaging manifestations, electrophysiology, and effective treatment plan of 9 children who met the above criteria were retrospectively analyzed in the Pediatric Neurology Department of Qilu Hospital at Shandong University from June 2019 to December 2021. All 9 patients (6 boys, 3 girls; aged 13 months−11 years and 5 months, median 3.5 years) had acute-onset seizures within 3 months. All had previous normal growth/development with no family history of disease. Seizure types were focal motor seizures (6), generalized tonic-clonic seizures (2), and generalized secondary-to-focal (1); occurred >10 times/day; and lasted <1 min/episode. Formal treatment with ≥2 types of antiseizure medicine (ASM) achieved an unsatisfactory effect. Cranial magnetic resonance imaging showed an abnormal result in 1 case. The APE score was ≥4 in 3 cases and <4 in 6 cases. All patients experienced symptomatic relief with immunotherapy; subsequently, 8 patients were free of recurrence and 1 had significantly reduced seizure frequency. Autoimmune antibody screening is recommended for children who were previously well and have acute-onset epilepsy; high frequency, short-duration seizures; no good response to 2 types of ASM; and other etiologic factors excluded, even with APE score <4. Even with negative autoimmune antibody results, the possibility of autoimmune epilepsy should be considered for urgent initiation of immunotherapy, which can achieve good results.

show abstract

Section: Discussionmentioning

confidence: 99%